Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

hsa-miR-195-5p miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


New RDM0036H 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

miREIA – miRNA enzyme immunoassay

Applications

Tissue extract, Whole blood, Cell culture lysates

Sample Requirements

10 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

6.25 – 0.195 amol/μl

Limit of Detection

0.065 amol/ul

Intra-assay (Within-Run)

n = 8,
CV = 5.9%

Inter-assay (Run-to-Run)

n = 5,
CV = 5.6%

Spiking Recovery

97.7%

Dilution Linearity

117.8%

Specificity

Crossreactivity with the miRNA family members exhibiting high sequence identity cannot be excluded.

Note

Product Manual: miREIA - microRNA enzyme immunoassay

Have you bought miREIA kits and need help with assay procedure? Please look at product manual video how easy using the miREIA method is.


Product Manual: miREIA - microRNA enzyme immunoassay

 

Summary

Features

  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-195-5p isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic

Cardiovascular disease, Oncology

Summary

MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in the pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

High expressed miR-195-5p could promote cardiac hypertrophy, whereas the suppression of miR-195-5p prevented hypertrophy of H9c2 cardiomyocytes under angiotensin II treatment. It was observed that miR-195-5p promotes cardiac hypertrophy via targeting MFN2 and FBXW7. miR-195-5p was significantly upregulated in the blood of Deep vein thrombosis patients. miR-195-5p downregulation promoted cell viability and inhibited the apoptosis of human umbilical vein endothelial cells.

The expression of miR-195-5p was decreased in non-small cell lung cancer (NSCLC). Downregulation of miR-195-5p was significantly associated with TNM stage, tumor size and lymph node metastasis. On the other hand, the expression of miR-195-5p was higher in human normal lung cell lines than in NSCLC cells. Overexpression of miR-195-5p increased cell apoptotic rate of A549 cell lines, with the expression of pro-apoptotic protein Bax up-regulated and that of the anti-apoptotic protein Bcl-2 down-regulated. Therefore miR-195-5p could be used as a potential prognostic predictor and tumor suppressor in NSCLC. MiR-195-5p/-218-5p displayed a negative correlation with baculoviral IAP repeat containing 5 expression, and acted as independent prognostic factors of poor prognosis in patients with gastric cancer. miR-195-5p plays an important anticancer role in human colorectal cancer (CRC) progression as it was significantly downregulated in CRC tissues. Patients with a low level of miR-195-5p had significantly shortened overall survival. Altered miR-195-5p in colon cancer cells led to distinct changes of proliferation, migration, invasion, and epithelial-mesenchymal transition. It was observed that the gene GDPD5 is an effector of chemoresistance and metastasis in CRC. miR-195-5p is also a potent suppressor of GDPD5 and that, as such, it significantly increases chemosensitivity and apoptosis in chemoresistant CRC cells. hTERT gene plays an important role in melanoma. hTERT expression level was inversely correlated with miR-497-5p, miR-195-5p and miR-455-3p. Overexpression of miR-497-5p, miR-195-5p and miR-455-3p inhibited A375 cell proliferation, migration and invasion, arrested the cell cycle, induced cell apoptosis and decreased hTERT expression. miR-497-5p, miR-195-5p, miR-455-3p were significantly downregulated, while hTERT was upregulated in melanoma tissues. MiR-497-5p, miR-195-5p and miR-455-3p act as tumor suppressors by targeting hTERT in melanoma A375 cells.

Summary References (8)

References to miR-195-5p

  • Feng C, Zhang L, Sun Y, Li X, Zhan L, Lou Y, Wang Y, Liu L, Zhang Y. GDPD5, a target of miR-195-5p, is associated with metastasis and chemoresistance in colorectal cancer. Biomed Pharmacother. 2018 May;101:945-952. doi: 10.1016/j.biopha.2018.03.028. Epub 2018 Mar 22. PMID: 29635904. See more on PubMed
  • Chai L, Kang XJ, Sun ZZ, Zeng MF, Yu SR, Ding Y, Liang JQ, Li TT, Zhao J. MiR-497-5p, miR-195-5p and miR-455-3p function as tumor suppressors by targeting hTERT in melanoma A375 cells. Cancer Manag Res. 2018 May 3;10:989-1003. doi: 10.2147/CMAR.S163335. PMID: 29760567; PMCID: PMC5937487. See more on PubMed
  • Jin J, Wang C, Ouyang Y, Zhang D. Elevated miR-195-5p expression in deep vein thrombosis and mechanism of action in the regulation of vascular endothelial cell physiology. Exp Ther Med. 2019 Dec;18(6):4617-4624. doi: 10.3892/etm.2019.8166. Epub 2019 Nov 4. PMID: 31807149; PMCID: PMC6878892. See more on PubMed
  • Lin X, Wang S, Sun M, Zhang C, Wei C, Yang C, Dou R, Liu Q, Xiong B. miR-195-5p/NOTCH2-mediated EMT modulates IL-4 secretion in colorectal cancer to affect M2-like TAM polarization. J Hematol Oncol. 2019 Feb 26;12(1):20. doi: 10.1186/s13045-019-0708-7. Erratum in: J Hematol Oncol. 2019 Nov 22;12(1):122. PMID: 30808369; PMCID: PMC6390326. See more on PubMed
  • Luo J, Pan J, Jin Y, Li M, Chen M. MiR-195-5p Inhibits Proliferation and Induces Apoptosis of Non-Small Cell Lung Cancer Cells by Targeting CEP55. Onco Targets Ther. 2019 Dec 24;12:11465-11474. doi: 10.2147/OTT.S226921. PMID: 31920335; PMCID: PMC6935316. See more on PubMed
  • Wang L, Qin D, Shi H, Zhang Y, Li H, Han Q. MiR-195-5p Promotes Cardiomyocyte Hypertrophy by Targeting MFN2 and FBXW7. Biomed Res Int. 2019 Jun 25;2019:1580982. doi: 10.1155/2019/1580982. PMID: 31341888; PMCID: PMC6614993. See more on PubMed
  • Zheng J, Xu T, Chen F, Zhang Y. MiRNA-195-5p Functions as a Tumor Suppressor and a Predictive of Poor Prognosis in Non-small Cell Lung Cancer by Directly Targeting CIAPIN1. Pathol Oncol Res. 2019 Jul;25(3):1181-1190. doi: 10.1007/s12253-018-0552-z. Epub 2019 Jan 12. Erratum in: Pathol Oncol Res. 2020 Jul;26(3):2015. PMID: 30637589; PMCID: PMC6614139. See more on PubMed
  • Zou J, Liao X, Zhang J, Wang L. Dysregulation of miR-195-5p/-218-5p/BIRC5 axis predicts a poor prognosis in patients with gastric cancer. J Biol Regul Homeost Agents. 2019 Sep-Oct;33(5):1377-1385. doi: 10.23812/19-146-A. PMID: 31663299. See more on PubMed
Related Products Docs